We performed a service-based epidemiological study of primary blepharospasm in the island of Sardinia (Italy). Due to its favorable geographical location, we are confident we will provide reliable data from patients seeking botulinum toxin treatment. A total of 53 patients were assessed. Prevalence was estimated to be 32.2 per 1 million (95% confidence interval, 23.0-40.8). These results are in line with those obtained in other similar surveys, that is, record-based, and performed in various European regions such as Northern England, the Munich area, as well as the Epidemiologic Study of Dystonia in Europe.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mds.21084 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic Diversity and Expanded Phenotypes in Dystonia: Insights from Large-Scale Exome Sequencing.
medRxiv
December 2024
Institute of Neurogenetics, University of Lübeck, 23538 Lübeck, Germany.
Dystonia is one of the most prevalent movement disorders, characterized by significant clinical and etiological heterogeneity. Despite considerable heritability (~25%) and the identification of several disease-linked genes, the etiology in most patients remains elusive. Moreover, understanding the correlations between clinical manifestation and genetic variants has become increasingly complex.
View Article and Find Full Text PDFSuccessful Treatment of Severe, Poorly Controlled Benign Essential Blepharospasm with DaxibotulinumtoxinA.
Ophthalmic Plast Reconstr Surg
December 2024
Department of Ophthalmology, Shiley Eye Institute, Division of Oculofacial Plastic and Reconstructive Surgery, UC San Diego.
Benign essential blepharospasm is a focal dystonia characterized by involuntary contractions of the orbicularis oculi. Botulinum toxin type A injections are often first-line treatment, but patients may experience refractory symptoms or decreased response over time. DaxibotulinumtoxinA, a novel botulinum toxin type A product, has shown promise in cervical dystonia and facial rhytids but has not been previously reported for benign essential blepharospasm treatment.
View Article and Find Full Text PDFCorrelation between blepharospasm and psychological diseases: the anxiety, depression and sleep disorder study.
Int J Ophthalmol
November 2024
Eye Center of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China.
Aim: To investigate the relationship between benign essential blepharospasm (BEB) symptoms and depression/anxiety/sleep disorder in a prospective manner and to determine whether treatment the BEB with botulinum toxin type A (BoNT/A) can impact psychological symptoms.
Methods: This prospective interventional case series recruited 61 adults with evidence of BEB. Patients were administered the Jankovic Rating Scale (JRS), the Blepharospasm Disability Index (BSDI), Personal Health Questionnaire Depression Scale (PHQ-8), Generalized Anxiety Disorder 7-item scale (GAD-7) and the Athens insomnia scale (AIS) to evaluate the severity of BEB symptoms, depression, anxiety and sleep disorder before and 1wk, 1, 3mo after the BoNTA treatment.
Depressive symptoms and quality of life in patients with benign essential blepharospasm under long-term therapy with botulinum toxin.
Acta Neurol Belg
November 2024
Department of Ophthalmology, University Hospital of Bonn, Ernst-Abbe-Str. 2, D-53127, Bonn, Germany.
Regular and long-term injections of botulinum toxin (BoNT) are considered the first line therapy for essential blepharospasm (BEB), but no data exists on the long-term effect of this therapy on depressive symptoms and quality of life. This study aims to prospectively evaluate the long-term effects of BoNT therapy on depressive symptoms as well as on daily activities, emotional well-being and quality of life using validated questionnaires (BEB-scale, Beck`s Depression Inventory (BDI)). 86 patients diagnosed with BEB were followed up for a median of 4 years.
View Article and Find Full Text PDFVisual dysfunction of superior colliculus and lateral geniculate nucleus in idiopathic blepharospasm.
J Neurol Sci
November 2024
Grenoble-Alpes University, INSERM, U1216, University Hospital of Grenoble-Alpes, Grenoble Institut Neurosciences, Grenoble, France; Movement Disorders Unit, Department of Neurology, University Hospital of Grenoble-Alpes, Grenoble, France.
Article Synopsis
- The study explores the role of the superior colliculus (SC) in idiopathic blepharospasm (BP), a condition with an unknown cause that may involve brain structures like the SC, basal ganglia, and others.
- Using fMRI and visual stimuli, the research compared responses between 10 women with BP and 10 matched controls, revealing that the BP group showed no visual response modulation in the SC and lateral geniculate nucleus (LGN) across various brightness levels.
- The results suggest dysfunction in the SC and LGN for those with BP, indicating that such brain imaging could be crucial for identifying biomarkers and understanding the condition's underlying mechanisms in adult-onset
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!